Rheumatology
Phase 2 RCT: Efficacy and safety of mavrilimumab in giant cell arteritis.
4 May, 2022 | 08:07h | UTC
Commentary on Twitter
New phase II trial data ? for #giantcellarteriitis: Mavrilimumab, an anti-GM-CSF antibody, showed:
✅ longer time to flare
✅ higher rate of sustained remission
❎ similar rate of adverse events compared to placebohttps://t.co/2MDLch2Zmg pic.twitter.com/Rl1AgamQKG— ARD & RMD Open (@ARD_BMJ) March 10, 2022
M-A: Adverse events relating to prolonged hard collar immobilization.
3 May, 2022 | 10:27h | UTC
Checkpoint inhibitor–associated arthritis: a systematic review of case reports and case series.
28 Apr, 2022 | 07:58h | UTC
Gout in the ED: Pearls and pitfalls.
26 Apr, 2022 | 07:37h | UTCGout in the ED: Pearls and Pitfalls – emDocs
Review: The challenges in the primary prevention of osteoarthritis.
26 Apr, 2022 | 07:29h | UTCThe Challenges in the Primary Prevention of Osteoarthritis – Clinics in Geriatric Medicine
Commentary on Twitter
The Challenges in the Primary Prevention of Osteoarthritis
Opportunities for preventing OA across the lifespan.
????https://t.co/9mdvpeoEW9 pic.twitter.com/VexC3qEOlr
— Physio Meets Science (@PhysioMeScience) April 18, 2022
Under a (CC BY 4.0) license
RCT: Subacromial balloon spacer is not better than debridement only for irreparable rotator cuff tears of the shoulder.
25 Apr, 2022 | 00:27h | UTC
RCT: Allopurinol is noninferior to febuxostat for controlling gout flares.
19 Apr, 2022 | 02:05h | UTCComparative Effectiveness of Allopurinol and Febuxostat in Gout Management – NEJM Evidence (link to abstract – $ for full-text)
Review: Paradoxical reactions to biologicals in chronic inflammatory systemic diseases.
19 Apr, 2022 | 01:48h | UTC
Review: The safety of antirheumatic drugs.
19 Apr, 2022 | 01:42h | UTCThe Safety of Antirheumatic Drugs – Deutsches Ärzteblatt International
Cohort Study: Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer.
14 Apr, 2022 | 07:59h | UTCCommentary: Men treated for prostate cancer have increased fracture risk, yet few complete DXA screening – HealthImaging
Commentary on Twitter
In this cohort study, osteoporosis screening rates for over 50,000 elderly men with prostate cancer receiving hormonal therapy nationwide were very low; men who were screened were less likely to suffer major fractures in follow-up. https://t.co/RMz1bvEgiA
— JAMA Network Open (@JAMANetworkOpen) April 1, 2022
Acute phase of Kawasaki disease: a review of national guideline recommendations.
12 Apr, 2022 | 08:32h | UTC
UK clinical guideline for the prevention and treatment of osteoporosis.
11 Apr, 2022 | 01:33h | UTCUK clinical guideline for the prevention and treatment of osteoporosis – Archives of Osteoporosis
RCT: Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anesthetic injection for hip osteoarthritis.
7 Apr, 2022 | 08:37h | UTCNews Release: Steroid injections may provide longer lasting benefits for hip pain than current best care – BMJ
Commentary on Twitter
Adding an ultrasound guided corticosteroid and local anaesthetic injection to advice and education offers rapid and sustained improvements in pain and function, finds new research https://t.co/fQHzvKv2wL
— The BMJ (@bmj_latest) April 7, 2022
RCT: Effect of intramuscular vs. intra-articular glucocorticoid injection on pain among adults with knee osteoarthritis.
7 Apr, 2022 | 08:35h | UTC
Commentary on Twitter
This RCT found IM steroid injections were inferior to intrarticular injections for reducing pain in patients with knee osteoarthritis at 4 weeks but were noninferior at 8 and 24 weeks after injection. https://t.co/opq1C2BP8c pic.twitter.com/ucx4lvRDJQ
— JAMA Network Open (@JAMANetworkOpen) April 5, 2022
Systematic Review: Epidemiology of musculoskeletal manifestations in pediatric inflammatory bowel disease.
7 Apr, 2022 | 07:55h | UTC
Cohort Study: The five major autoimmune diseases are associated with increased risk of cancer.
6 Apr, 2022 | 09:52h | UTCCommentary: Increased Cancer Risk with Autoimmune Disorders – RheumNow
BSR guideline on management of pediatric, adolescent and adult patients with idiopathic inflammatory myopathy.
4 Apr, 2022 | 01:05h | UTC
Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
1 Apr, 2022 | 08:45h | UTCCommentary: Network meta-analysis rates treatments for Kawasaki disease – medwire News
RCT: Effect of tacrolimus vs. intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis.
31 Mar, 2022 | 08:18h | UTC
Commentary on Twitter
In this RCT, oral tacrolimus was noninferior to intravenous cyclophosphamide for initial therapy of active lupus nephritis, with a more favorable safety profile. https://t.co/scz7lahVRU
— JAMA Network Open (@JAMANetworkOpen) March 30, 2022
Systematic Review: Interventions for reducing inflammation in familial Mediterranean fever.
30 Mar, 2022 | 10:13h | UTCInterventions for reducing inflammation in familial Mediterranean fever – Cochrane Library
Summary: Medicines for reducing inflammation in people with familial Mediterranean fever – Cochrane Library
What to expect when women with axial spondyloarthritis are expecting: Prevalence of complications of pregnancies in women with axial spondyloarthritis.
30 Mar, 2022 | 10:01h | UTC
Commentary on Twitter
ICYMI: Among 98 women with axSpA, there were 335 pregnancies & 279 live births – 52% uncomplicated and 48% complicated (13%) multiple complications. axSpA had more Preterm birth (13 vs 5%), pre-eclampsia (7 vs 3%), Low birth Wt (8 vs 3%) https://t.co/1oFBKSUzzy pic.twitter.com/oLbYis81Y9
— Dr. John Cush (@RheumNow) March 28, 2022
Review: Challenges in the management of older patients with inflammatory rheumatic diseases.
29 Mar, 2022 | 08:22h | UTCChallenges in the management of older patients with inflammatory rheumatic diseases – Nature Reviews Rheumatology (if the link is paywalled, try this one)
Commentary on Twitter
New content online! Challenges in the management of older patients with inflammatory rheumatic diseases https://t.co/j5a0sQYs6q pic.twitter.com/zhq03boOIN
— NatRevRheumatol (@NatRevRheumatol) March 21, 2022
RCT: Adalimumab introduction vs. methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis.
29 Mar, 2022 | 08:20h | UTCComparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study – The Lancet Rheumatology (link to abstract – $ for full-text)
Commentary: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis – RheumNow
Commentary on Twitter
NEW RESEARCH—A randomised, open-label, phase 4 trial supports the addition of #adalimumab over escalating #methotrexate in patients with #PsoriaticArthritis not reaching minimal disease activity after an initial methotrexate course https://t.co/LUpzAw71lD #LancetRheumatology pic.twitter.com/ouqTyITlxC
— The Lancet Rheumatology (@TheLancetRheum) February 28, 2022
Systematic Review: Management of cervical spondylotic radiculopathy.
28 Mar, 2022 | 08:30h | UTCManagement of Cervical Spondylotic Radiculopathy: A Systematic review – Global Spine Journal
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
28 Mar, 2022 | 08:28h | UTC